Download PDF
Kardiologie up2date 2022; 18(04): 345-355
DOI: 10.1055/a-1729-8470
Thrombozyten und Gerinnungssystem

COVID-19: Thromboserisiko und Antikoagulationsmanagement

Eugen Widmeier
,
Alexander Supady
› Further Information
Also available at
    Permissions and Reprints All articles of this category

Bereits früh im Verlauf der COVID-19-Pandemie wurde eine Häufung von Thromboembolien bei schwer an COVID-19 erkrankten Patienten beobachtet. In frühen Berichten über Patienten aus Wuhan und aus New York wurde ein Zusammenhang zwischen erhöhten D-Dimeren und der Wahrscheinlichkeit, an der Erkrankung zu versterben, beobachtet.
Kernaussagen

  • COVID-19 wird durch eine Infektion mit SARS-CoV-2 ausgelöst und kann unterschiedlich schwer verlaufen.

  • Die Erkrankung geht mit einem erhöhten Risiko für Thromboembolien, aber auch für Blutungen einher.

  • Die Diagnose und die Therapie von schweren Thromboembolien unterscheidet sich bei COVID-19 nicht von anderen Krankheitsbildern.

  • Patienten, die stationär behandelt werden, sollten in der Regel eine medikamentöse Thromboembolieprophylaxe erhalten.

  • Eine therapeutische Antikoagulation ist nur in Ausnahmefällen und bei spezifischer Indikation (z. B. Lungenembolie oder Vorhofflimmern) indiziert.

Schlüsselwörter

COVID-19 - Thromboembolieprophylaxe - Antikoagulation - Lungenembolie


Publication History

Article published online:
06 December 2022

© 2022. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • Literatur

  • 1 Iba T, Levy JH, Levi M. et al. Coagulopathy of Coronavirus Disease 2019. Crit Care Med 2020; 48: 1358-1364
    CrossrefPubMedSearch in Google Scholar
  • 2 Zhou F, Yu T, Du R. et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020; 395: 1054-1062
    Search in Google Scholar
  • 3 Cummings MJ, Baldwin MR, Abrams D. et al. Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study. Lancet 2020; 395: 1763-1770
    Search in Google Scholar
  • 4 Ackermann M, Verleden SE, Kuehnel M. et al. Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19. N Engl J Med 2020; 383: 120-128
    Search in Google Scholar
  • 5 Pons S, Fodil S, Azoulay E. et al. The vascular endothelium: the cornerstone of organ dysfunction in severe SARS-CoV-2 infection. Crit Care 2020; 24: 353
    CrossrefPubMedSearch in Google Scholar
  • 6 Varga Z, Flammer AJ, Steiger P. et al. Endothelial cell infection and endotheliitis in COVID-19. Lancet 2020; 395: 1417-1418
    CrossrefPubMedSearch in Google Scholar
  • 7 Jimenez D, Garcia-Sanchez A, Rali P. et al. Incidence of VTE and Bleeding Among Hospitalized Patients With Coronavirus Disease 2019: A Systematic Review and Meta-analysis. Chest 2021; 159: 1182-1196
    CrossrefPubMedSearch in Google Scholar
  • 8 Wichmann D, Sperhake JP, Lutgehetmann M. et al. Autopsy Findings and Venous Thromboembolism in Patients With COVID-19: A Prospective Cohort Study. Ann Intern Med 2020; 173: 268-277
    Search in Google Scholar
  • 9 Bemtgen X, Zotzmann V, Benk C. et al. Thrombotic circuit complications during venovenous extracorporeal membrane oxygenation in COVID-19. J Thromb Thrombolysis 2021; 51: 301-307
    CrossrefPubMedSearch in Google Scholar
  • 10 Doyle AJ, Hunt BJ, Sanderson B. et al. A Comparison of Thrombosis and Hemorrhage Rates in Patients With Severe Respiratory Failure Due to Coronavirus Disease 2019 and Influenza Requiring Extracorporeal Membrane Oxygenation. Crit Care Med 2021; 49: e663-e672
    CrossrefPubMedSearch in Google Scholar
  • 11 Seeliger B, Doebler M, Hofmaenner DA. et al. Intracranial Hemorrhages on Extracorporeal Membrane Oxygenation: Differences Between COVID-19 and Other Viral Acute Respiratory Distress Syndrome. Crit Care Med 2022; 50: e526-e538
    CrossrefPubMedSearch in Google Scholar
  • 12 Poissy J, Goutay J, Caplan M. et al. Pulmonary Embolism in Patients With COVID-19: Awareness of an Increased Prevalence. Circulation 2020; 142: 184-186
    CrossrefPubMedSearch in Google Scholar
  • 13 Lopes RD, de Barros ESPGM, Furtado RHM. et al. Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer concentration (ACTION): an open-label, multicentre, randomised, controlled trial. Lancet 2021; 397: 2253-2263
    CrossrefPubMedSearch in Google Scholar
  • 14 ATTACC Investigators, ACTIV-4a Investigators, REMAP-CAP Investigators. et al. Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19. N Engl J Med 2021; 385: 790-802
    Search in Google Scholar
  • 15 Nopp S, Moik F, Jilma B. et al. Risk of venous thromboembolism in patients with COVID-19: A systematic review and meta-analysis. Res Pract Thromb Haemost 2020; 4: 1178-1191
    CrossrefPubMedSearch in Google Scholar
  • 16 Bilaloglu S, Aphinyanaphongs Y, Jones S. et al. Thrombosis in Hospitalized Patients With COVID-19 in a New York City Health System. JAMA 2020; 324: 799-801
    CrossrefPubMedSearch in Google Scholar
  • 17 Vincent JL, Levi M, Hunt BJ. Prevention and management of thrombosis in hospitalised patients with COVID-19 pneumonia. Lancet Respir Med 2022; 10: 214-220
    CrossrefPubMedSearch in Google Scholar
  • 18 Perico L, Benigni A, Casiraghi F. et al. Immunity, endothelial injury and complement-induced coagulopathy in COVID-19. Nat Rev Nephrol 2021; 17: 46-64
    Search in Google Scholar
  • 19 Bonaventura A, Vecchié A, Dagna L. et al. Endothelial dysfunction and immunothrombosis as key pathogenic mechanisms in COVID-19. Nat Rev Immunol 2021; 21: 319-329
    CrossrefPubMedSearch in Google Scholar
  • 20 Wagner DD, Heger LA. Thromboinflammation: From Atherosclerosis to COVID-19. Arterioscler Thromb Vasc Biol 2022; 42: 1103-1112
    CrossrefPubMedSearch in Google Scholar
  • 21 Osuchowski MF, Winkler MS, Skirecki T. et al. The COVID-19 puzzle: deciphering pathophysiology and phenotypes of a new disease entity. Lancet Respir Med 2021; 9: 622-642
    CrossrefPubMedSearch in Google Scholar
  • 22 Remmelink M, De Mendonca R, D’Haene N. et al. Unspecific post-mortem findings despite multiorgan viral spread in COVID-19 patients. Crit Care 2020; 24: 495
    CrossrefPubMedSearch in Google Scholar
  • 23 Del Valle DM, Kim-Schulze S, Huang HH. et al. An inflammatory cytokine signature predicts COVID-19 severity and survival. Nat Med 2020; 26: 1636-1643
    CrossrefPubMedSearch in Google Scholar
  • 24 Ward SE, Fogarty H, Karampini E. et al. ADAMTS13 regulation of VWF multimer distribution in severe COVID-19. J Thromb Haemost 2021; 19: 1914-1921
    CrossrefPubMedSearch in Google Scholar
  • 25 Zuo Y, Warnock M, Harbaugh A. et al. Plasma tissue plasminogen activator and plasminogen activator inhibitor-1 in hospitalized COVID-19 patients. Sci Rep 2021; 11: 1580
    CrossrefPubMedSearch in Google Scholar
  • 26 Berlin DA, Gulick RM, Martinez FJ. Severe Covid-19. N Engl J Med 2020; 383: 2451-2460
    CrossrefPubMedSearch in Google Scholar
  • 27 Huang C, Wang Y, Li X. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 395: 497-506
    CrossrefPubMedSearch in Google Scholar
  • 28 Vincent JL. COVID-19: it’s all about sepsis. Future Microbiol 2021; 16: 131-133
    CrossrefPubMedSearch in Google Scholar
  • 29 Gurbel PA, Tantry US, Storey RF. International COVID-19 thrombosis biomarkers colloquium: COVID-19 diagnostic tests. J Thromb Thrombolysis 2021; 52: 992-998
    CrossrefPubMedSearch in Google Scholar
  • 30 Barrett TJ, Lee AH, Xia Y. et al. Platelet and Vascular Biomarkers Associate With Thrombosis and Death in Coronavirus Disease. Circ Res 2020; 127: 945-947
    CrossrefPubMedSearch in Google Scholar
  • 31 Leentjens J, van Haaps TF, Wessels PF. et al. COVID-19-associated coagulopathy and antithrombotic agents-lessons after 1 year. Lancet Haematol 2021; 8: e524-e533
    CrossrefPubMedSearch in Google Scholar
  • 32 Konstantinides SV, Meyer G, Becattini C. et al. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur Heart J 2020; 41: 543-603
    Search in Google Scholar
  • 33 Connors JM, Brooks MM, Sciurba FC. et al. Effect of Antithrombotic Therapy on Clinical Outcomes in Outpatients With Clinically Stable Symptomatic COVID-19: The ACTIV-4B Randomized Clinical Trial. JAMA 2021; 326: 1703-1712
    CrossrefPubMedSearch in Google Scholar
  • 34 Ananworanich J, Mogg R, Dunne MW. et al. Randomized study of rivaroxaban vs. placebo on disease progression and symptoms resolution in high-risk adults with mild COVID-19. Clin Infect Dis 2022; 75: e473-e481
    CrossrefPubMedSearch in Google Scholar
  • 35 Spyropoulos AC, Goldin M, Giannis D. et al. Efficacy and Safety of Therapeutic-Dose Heparin vs Standard Prophylactic or Intermediate-Dose Heparins for Thromboprophylaxis in High-risk Hospitalized Patients With COVID-19: The HEP-COVID Randomized Clinical Trial. JAMA Intern Med 2021; 181: 1612-1620
    CrossrefPubMedSearch in Google Scholar
  • 36 Sholzberg M, Tang GH, Rahhal H. et al. Effectiveness of therapeutic heparin versus prophylactic heparin on death, mechanical ventilation, or intensive care unit admission in moderately ill patients with covid-19 admitted to hospital: RAPID randomised clinical trial. BMJ 2021; 375: n2400
    CrossrefPubMedSearch in Google Scholar
  • 37 Kluge S, Janssens U, Welte T. et al. S3-Leitlinie – Empfehlungen zur stationären Therapie von Patienten mit COVID-19 (12.09.2022). AWMF-Register-Nr. 113/001. Accessed November 21, 2022 at: https://register.awmf.org/assets/guidelines/113-001LGl_S3_Empfehlungen-zur-stationaeren-Therapie-von-Patienten-mit-COVID-19_2022-09_1.pdf
    PubMed
  • 38 REMAP-CAP Investigators, ACTIV-4a Investigators, ATTACC Investigators. et al. Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19. N Engl J Med 2021; 385: 777-789
    Search in Google Scholar
  • 39 Sadeghipour P, Talasaz AH. INSPIRATION Investigators. et al. Effect of Intermediate-Dose vs Standard-Dose Prophylactic Anticoagulation on Thrombotic Events, Extracorporeal Membrane Oxygenation Treatment, or Mortality Among Patients With COVID-19 Admitted to the Intensive Care Unit: The INSPIRATION Randomized Clinical Trial. JAMA 2021; 325: 1620-1630
    CrossrefPubMedSearch in Google Scholar
  • 40 Perepu US, Chambers I, Wahab A. et al. Standard prophylactic versus intermediate dose enoxaparin in adults with severe COVID-19: A multi-center, open-label, randomized controlled trial. J Thromb Haemost 2021; 19: 2225-2234
    CrossrefPubMedSearch in Google Scholar
  • 41 Ramacciotti E, Barile Agati L, Calderaro D. et al. Rivaroxaban versus no anticoagulation for post-discharge thromboprophylaxis after hospitalisation for COVID-19 (MICHELLE): an open-label, multicentre, randomised, controlled trial. Lancet 2022; 399: 50-59
    CrossrefPubMedSearch in Google Scholar